



## ESC Cardiovascular Round Table

CRT Workshop – 17 & 18 February 2021

“New Perspectives for Hypertension Management.  
The Contribution from Progress in Methodological Approaches and  
Technological Developments”

### Biographies

- [Professor Gianfranco PARATI, Italy](#)
- [Professor Alexandra GONCALVES, USA](#)
- [Dr David SOERGEL, Switzerland](#)
- [Professor Thomas KAHAN, Sweden](#)
- [Professor Eva GERDTS, Norway](#)
- [Professor Felix MAHFOUD, Germany](#)
- [Dr Paola SANTALUCIA, Italy](#)
- [Professor Richard McMANUS, United Kingdom](#)
- [Dr Rosa Maria BRUNO, France](#)
- [Professor Enrico CAIANI, Italy](#)
- [Professor Lorenzo MANTOVANI, Italy](#)



## [Professor Gianfranco PARATI](#)

Professor of Cardiovascular Medicine and Director, School of Specialization in Cardiovascular Medicine, University of Milano-Bicocca. Scientific Director and Head of Department of Cardiovascular, Neural and Metabolic Sciences; IRCCS, Istituto Auxologico Italiano, S.Luca Hospital, Milan, Italy.

Specialist in Cardiology and Internal Medicine, Professor Parati is the Scientific Director and Head of the Cardiology Unit at St Luca Hospital in Milano and Professor of Cardiovascular Medicine at the Milano-Bicocca University.

Honorary Prof. at Universidad Peruana Cayetano Heredia, Lima, Peru, Professor Parati is the Past President of the Italian Society of Hypertension, the Past Chairman of the ESH WG on BP Monitoring and CV Variability.

ESC Fellow, Prof. Parati is also Nucleus Member and Chairperson Elect of the ESC Council on Hypertension, Ex-officio nucleus member of ESC e-cardiology WG, Chairman of the WG on BP Monitoring at the Italian Society of Hypertension. He is also the Secretary General of the World Hypertension League.

He has received the *Bjorn Folkow 2015 Award* in Hypertension Pathophysiology and is the Executive Editor of the *J.Hypertension*, Associate Editor of *Hypertension Research*, and Associate Editor for Hypertension Session of the *Eur.J.Preventive Cardiology*.

Research interests: Cardiovascular neural control, BP measurement; BP Variability; Sleep Related Breathing Disorders; Arterial Hypertension; Cardiovascular Effects of High Altitude; Space research; Telemedicine, Digital and Mobile Health; Heart Failure.



### [Professor Alexandra GONCALVES - Philips](#)

Alexandra Goncalves is the Philips Chief Medical Officer, Strategy, M&A and Partnerships, a position she has held since June 2019.

As an academic cardiologist with a business acumen, she provides functional leadership for clinical innovation and clinical strategy for Philips. Alexandra works closely and collaboratively with business, research and functional leaders across the organization, as well as exploring inorganic growth opportunities.

Alexandra has joined Philips in 2016 and worked three years as Sr. Medical Director for the Ultrasound business. She was instrumental for the Cardiovascular Ultrasound business success by leading the evaluation of medical trends, by providing clinical insights and strategic direction, and by developing impactful partnerships through fostering relationships with clinical, scientific, regulatory and marketing leaders worldwide.

Alexandra started her career as an academic cardiologist in Portugal and Spain and her past experience includes research in epidemiology and clinical trials in the Cardiovascular Department at the Brigham and Women's Hospital/ Harvard Medical School (HMS). She earned a Master in Medical Sciences from HMS and while working as a clinical cardiologist, she earned a doctorate degree (PhD). Her work was a driving force towards the refinement of the use of echocardiography in transcatheter structural heart interventions.

Alexandra is an internationally recognized thought leader with business acumen and an extensive record of multi-disciplinary medical collaborations, as educator, committee leader, author, and editor. She serves as Affiliate Professor of Medicine in Portugal and has been awarded several prizes, including the prestigious Senior Clinical Research and Career Development Award from HMS and Portuguese Foundation for Science and Technology.



**Dr David SOERGEL - Novartis**

David Soergel, MD is the Global Head of Cardio-Renal-Metabolic Development at Novartis, joining in 2017.


Prior to this role, Dr. Soergel spent 9 years at biotechnology companies working in a variety of therapy areas, building high-performing development teams and conducting complex multi-stage adaptive trials.

He has been involved in development of program strategy and design, execution and reporting of clinical trials in acute and chronic pain, acute heart failure, infectious diseases and renal diseases.

Prior to joining biotech, Dr. Soergel worked in early stage clinical development and translational medicine at GlaxoSmithKline, leading programs from the discovery organization into the clinic and through proof of concept.

Dr. Soergel originally trained in pediatrics, pediatric cardiology and heart failure and transplant at Johns Hopkins Hospital and Children's Hospital of Philadelphia.

During his cardiology fellowship, Dr. Soergel completed an NIH sponsored NRSA post-doctoral fellowship at Johns Hopkins studying myofilament function.



## Professor Thomas KAHAN

*Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine, Stockholm, Sweden*

Dr. Thomas Kahan is professor of medicine at Karolinska Institutet, Stockholm. He is responsible for cardiovascular research at Danderyd University Hospital, where he serves as a senior consultant in cardiology, and is head of the Cardiovascular Risk Assessment Unit, a European Society of Hypertension Excellence Centre in Hypertension.

Dr. Kahan is incoming president of the ESC Council of Hypertension, board member of the European Society of Hypertension, and president-elect of the International Society of Cardiovascular Pharmacotherapy.

His main research interests are neurohormonal mechanisms in the control of blood pressure and cardiac function, with focus on structural myocardial and vascular changes, and neuroendocrine mechanisms in hypertension and heart failure. Other areas of interest are risk assessment and prevention, health economics, and implementation of treatment. Dr. Kahan's research has published approximately 250 scientific papers.



**Professor Eva GERDTS**

*University of Bergen | UiB · Department of Clinical Science, Bergen, Norway*

Professor of cardiology, University of Bergen. Chair, Non-invasive cardiac imaging unit, Department of Heart Disease, Haukeland University Hospital, Bergen, Norway. Our laboratory focuses on conventional and advanced echocardiography, assessment of arterial stiffness, vascular ultrasound, exercise echocardiography, ambulatory blood pressure monitoring, core laboratory service in large clinical studies. I am particularly interested in hypertensive heart disease, hypertension in aortic valve stenosis and cardiac function in obesity.



## Professor Felix MAHFOUD

*Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Hospital, Hamburg, Germany*

Felix Mahfoud is Professor of medicine and deputy director of the Department for Internal Medicine and Cardiology at Saarland University Hospital and Visiting Professor at Harvard- MIT, Biomedical Engineering, Boston, MA.

Professor Mahfoud holds board certifications in internal medicine, cardiology, intensive care medicine, emergency medicine, and hypertension. He is member of several editorial boards and serves as Vice-Chair of the Working Group Interventional Hypertension Treatment of the European Society of Hypertension (ESH), Liaison Officer of the Council on Hypertension of the European Society of Cardiology (ESC), EuroPCR Board of Directors, TCT Associate Director, and program committee member (topic coordinator hypertension) of the ESC congress 2019 & 2020. He has authored more than 330 articles in peer reviewed journals and was writing committee member of the 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes and the 2018 ESC/ESH Guidelines for the management of arterial hypertension.




**Dr Paola SANTALUCIA**

*Italian Association against Thrombosis and cardiovascular diseases, (ALT Onlus), Milan, Italy*

Dr Santalucia is the Vice president of the ALT association, Stroke neurologist and cardiologist. She is the Chief of the Neurology-Stroke Unit at San Giuseppe Hospital in Milan, Italy.

She works very closely on every issue related to patient involvement and correct information in the field of cardiovascular disease and thrombosis-related disease in general within ALT Organisation, and as a member of the EHN board (European Heart Network) whose ALT is one of the Organization-member.





## Professor Richard McMANUS

### *University of Oxford, United Kingdom*

Richard McManus is a GP and Professor of Primary Care Research at the University of Oxford. His research interests lie mainly in the prevention of cardiovascular disease with particular emphasis on blood pressure measurement and the management of hypertension in primary care where his work has influenced National and International Clinical Guidelines.

He is Chief Investigator on Programme Grants around Self-Monitoring/Management of Blood Pressure in Hypertension and Pregnancy (NIHR) as well as leading the Self-Management theme of the NIHR Oxford and Thames Valley Applied Research Collaboration.

He supervises PhD students undertaking projects around self-monitoring in hypertension and pregnancy and teaches clinical students at Green Templeton College where he is a Fellow and Dean for Welfare.

He leads Oxford's contribution to the NIHR School for Primary Care Research. He chairs the Blood Pressure Monitoring Working Party of the British Hypertension Society and is a Chair of the NIHR Doctoral Fellowship Panel. He has provided expert advice to NICE (member of 2011 & 2019 Hypertension Guideline Development Groups), and the European Society of Cardiology/European Society of Hypertension (member of 2018 Guideline Development Group).



**Dr Rosa Maria BRUNO**

*Paris Cardiovascular Research Center (PARCC-INSERM), Paris, France*

Rosa Maria Bruno (MD, PhD) is Internal Medicine and Hypertension specialist, currently researcher at the Paris Cardiovascular Research Center (PARCC-INSERM) in France.

Her main field of research is the non-invasive evaluation of functional and structural vascular alterations in traditional and emerging cardiovascular risk factors, as well as sympathetic regulation of vascular function in hypertension.

She authored >130 publications in peer-reviewed, Pubmed-indexed scientific journals, with a H-index of 26 and >1800 citations.

She is member of the Executive Committee of the Artery Society and of the ESC Council of Hypertension Nucleus. She is among the initiators of the European Collaboration in Science and Technology (COST) Action VascAgeNet and leader of Working Group 4 (Data and research studies – big data approaches) and she leads the Covid-19 effects on ARTERial Stiffness and vascular AgiNg (CARTESIAN) study.



## Professor Enrico CAIANI

*Politecnico Di Milano, Electronics, Information and Bioengineering, Milano, Italy*

Enrico G. Caiani (MS 1996, PhD 2000) is Associate professor at the Electronics, Information and Bioengineering Dpt., Politecnico di Milano, Italy, where he teaches the classes of “E-health: methods and applications” and “Biomedical Image Processing Laboratory”.

Author of 7 book chapters and >100 papers (IF>350, H-index=28, total citations>4000), 130 conference proceeding papers and >100 abstracts presented in international conferences, he has been and is involved in several Italian, EU, ESA, and other international research projects.

His main research interests include e-health solutions in the field of cardiology and persuasive design technology, health geomatics, cardiac image processing and space physiology.

In the European Society of Cardiology, he was the Chair of the e-Cardiology Working Group (16-18), and now is member of the Advocacy and Public Policy Committee, member of the Regulatory Affairs Committee on Medical Devices and member of the Digital Health Committee. Since 2016, with the European Commission he is the ESC representative in the eHealth Stakeholders Group (DG SANTE), and in the Medical Device Coordination Group- New technologies (DG GROW).



## Professor Lorenzo Giovanni MANTOVANI

*Associate Professor (tenure) of Public Health, School of Medicine and Surgery, Director of the Center for Public Health Research (CESP), Director of the Postgraduate School of Hygiene and Preventive Medicine, all at the Università degli Studi di Milano – Bicocca. Director, Value-based Healthcare Unit, IRCCS Multimedica Research Hospital*

Over 25 years, Lorenzo has held academic positions within numerous academic and other institutions. He has received a nomination for the president elect position within International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and currently serves as President of the ISPOR Italy-Milan Chapter.

A founding member and Scientific Director of Charta Foundation, Professor Mantovani is a member of the Independent Steering Committee of Xamos, Xalia and Cosimo, Global Post-Marketing Surveillance studies required by the European Medicines Agency as part of the Risk Management Plan of the drug rivaroxaban. He serves in the Steering Committee of the International Garfield Registries, as PI of the HEOR sub-studies.

Professor Mantovani has been or is advisor to several agencies of the Italian National Health Service and to the President of Commission on Hygiene and Healthcare of the Italian Senate and to the President of the Healthcare and Social Policy Commission of the Lombardy Regional Parliament.

Additionally he has held membership on: the European Public Health Association (EUPHA); European Board for Haemophilia Therapy Standardisation (2005-2011); Italian Society of Pharmacology (as coordinator of the pharmacoeconomics working group); Italian Society of Public Health (SITI) as member of the steering committee of the HTA Working Group; International Prophylaxis Study Group (2005-2010); Haemophilia Inter-disciplinary Working Group (later the European Association for Haemophilia and Allied Disorders); EuroQoL Group (2009-2014); Health Economics Committee of the European Heart and Rhythm Association (2009-2011); International Center for Digestive Health (since 2016); Italian Federation of Haemophilia Patients' Associations (FEDEMO) as member of the Scientific Board (since 2011); HTA Working Group, Italian Society of Diabetology; President of the Associazione Italiana di Farmacoeconomia e Outcomes Research (AIFOR) (2015-2017); and Global Burden of Disease.

Professor Mantovani has received the EFPIA Scientist of Tomorrow Award (2008), the ISPOR Distinguished Service Award twice (2005 and 2015) and is Fellow of the European Society of Cardiology

Professor Mantovani has co-authored more than 220 papers published in scientific journals including the European Heart Journal, Blood, European Journal of Public Health, European Journal of Cancer, Hepatology, Circulation, Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, International Journal of Cardiology, Lancet Haematology, Lancet Neurology, Lancet, Jama Oncology, Jama Cardiology, BMJ, New England Journal of Medicine.